The information on this website is presented for educational purposes only. It is not intended as a substitute for the diagnosis, treatment, or advice of a qualified, licensed medical professional. The facts presented are offered as information only, not medical advice, and in no way should anyone infer that we are practicing medicine. Seek the advice of a medical professional for proper application of this material to any specific situation.
Medical Ozone Therapy Information: Dr Shallenberger
Hope ozone generator
Chronic Lyme disease and MSIDS: These chronic infections demonstrate the inability of the patient’s immune system to defend itself against bacteria, fungi and viruses.
These infections often respond to ozone therapy as ozone stimulates the immune system by as much as 400% to produce the cytokine molecules that it uses to fight infections.
The treatment protocol for any infection is rectal insufflation twice a day until the infection resolves and then three times a week for an additional 6 weeks to prevent a recurrence. Ozone can also be infused into the ears with Hope’s headphones.
Ozone Therapy is a medical therapy that has been used worldwide for over 50 years with dramatic success and safety. In North America Ozone Therapy has not yet been fully recognized by the medical authorities, however if you review our ever growing list of Ozone Doctors, you will see that it is being adopted more and more by formally ‘traditional’ medical practitioners. It is clear that Ozone Therapy works, and it is becoming one of the most useful tools in medical clinics across America and around the World. (See “A Review of Ozone Therapy Applications” to learn how ozone is being administered).What does it do? To briefly summarize, ozone accomplishes these very important tasks in your body:
1/ Ozone is AntiAging (some of those AntiAging effects can be attributed to the following list of actions…)
Identification of novel activity against Borrelia burgdorferi persisters using an FDA approved drug library.
Although antibiotic treatment for Lyme disease is effective in the majority of cases, especially during the early phase of the disease, a minority of patients suffer from post-treatment Lyme disease syndrome (PTLDS). It is unclear what mechanisms drive this problem, and although slow or ineffective killing of Borrelia burgdorferi has been suggested as an explanation, there is a lack of evidence that viable organisms are present in PTLDS. Although not a clinical surrogate, insight may be gained by examining stationary-phase in vitro Borrelia burgdorferi persisters that survive treatment with the antibiotics doxycycline and amoxicillin. To identify drug candidates that can eliminate B. burgdorferi persisters more effectively, we screened an Food and Drug Administration (FDA)-approved drug library consisting of 1524 compounds against stationary-phase B. burgdorferi by using a newly developed high throughput SYBR Green I/propidium iodide (PI) assay. We identified 165 agents approved for use in other disease conditions that had more activity than doxycycline and amoxicillin against B. burgdorferi persisters. The top 27 drug candidates from the 165 hits were confirmed to have higher anti-persister activity than the current frontline antibiotics. Among the top 27 confirmed drug candidates from the 165 hits, daptomycin, clofazimine, carbomycin, sulfa drugs (e.g., sulfamethoxazole), and certain cephalosporins (e.g. cefoperazone) had the highest anti-persister activity. In addition, some drug candidates, such as daptomycin and clofazimine (which had the highest activity against non-growing persisters), had relatively poor activity or a high minimal inhibitory concentration (MIC) against growing B. burgdorferi. Our findings may have implications for the development of a more effective treatment for Lyme disease and for the relief of long-term symptoms that afflict some Lyme disease patients.
Borrelia burgdorferi; FDA approved drug library; SYBR Green I; drug discovery; persisters